Share Name Share Symbol Market Type Share ISIN Share Description
Angle Plc LSE:AGL London Ordinary Share GB0034330679 ORD 10P
  Price Change % Change Share Price Shares Traded Last Trade
  +0.00p +0.00% 47.50p 635 06:40:14
Bid Price Offer Price High Price Low Price Open Price
46.00p 49.00p 47.50p 47.50p 47.50p
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Support Services 0.5 -7.4 -8.7 - 55.62

Angle (AGL) Latest News

More Angle News
Angle Takeover Rumours

Angle (AGL) Share Charts

1 Year Angle Chart

1 Year Angle Chart

1 Month Angle Chart

1 Month Angle Chart

Intraday Angle Chart

Intraday Angle Chart

Angle (AGL) Discussions and Chat

Angle Forums and Chat

Date Time Title Posts
26/4/201817:56ANGLE 2016 – LIQUID BIOPSY TAKEOVER TARGET9,183
16/3/201720:00ANGLE [12.75p] TARA*S SHARE OF THE DECADE "TARGET PRICE Ј100.00 PER SHARE."3,646
08/10/201612:43Angle PLC 201130,115
02/12/201513:04Angle 2016 – Liquid Biopsy Takeover Target-
11/6/201508:16MrKeysersoze39

Add a New Thread

Angle (AGL) Most Recent Trades

Trade Time Trade Price Trade Size Trade Value Trade Type
07:40:2947.00635298.45O
2018-04-26 16:10:4447.5063,00029,925.00O
2018-04-26 14:56:3846.302,5001,157.50O
2018-04-26 14:09:3846.307,6393,536.86O
2018-04-26 14:02:3846.302,000926.00O
View all Angle trades in real-time

Angle (AGL) Top Chat Posts

DateSubject
27/4/2018
09:20
Angle Daily Update: Angle Plc is listed in the Support Services sector of the London Stock Exchange with ticker AGL. The last closing price for Angle was 47.50p.
Angle Plc has a 4 week average price of 45.50p and a 12 week average price of 42.50p.
The 1 year high share price is 80p while the 1 year low share price is currently 32.25p.
There are currently 117,086,522 shares in issue and the average daily traded volume is 108,798 shares. The market capitalisation of Angle Plc is £55,616,097.95.
15/4/2018
11:34
4legs: We are in the right place at the right time, though so far getting nowhere fast, with an increasing share price. Mind you Parsortix has become widely proven ..... so (imho) just a matter of time to bring about a rising share price. Price aside, very much looking forward to Parsortix revolutionising cancer diagnostics.
27/3/2018
22:43
pwhite73: 4legs/maxie23 If a promo in The Sunday Times for crying out loud can't lift the share price then what the hell can? AGL is an AIM company and the share price will get diluted all the way down to the nominal value of 10p. When it drops below the nominal value it will be consolidated and the whole process will start again. Taken from the interims 31/01/2018 - "Successful fundraising from institutional and other investors raising gross proceeds of GBP15.0 million. Proceeds net of expenses were GBP14.4 million." £15m is a humongous sum of money to raise. How long do you think it will take them to generate that amount of money in sales. Revenues were £200k for the last six months FFS. This stock you trade on the spikes. Hold long term and you will get hammered.
26/3/2018
09:17
alloa2003: I think AGL share price suffers from boredom at times between announcements. Very news driven as profitability is some way off.
25/3/2018
13:09
pwhite73: Whether the 08/01/2018, 08/12/2017 or 09/10/2017. They are using the Parsotix system on Prostate, Breast and Ovarian cancer. The link between positive newsflow and the performance of any company's share price listed on the AIM has long since been broken by unsrupulous and downright illegal behaviour of nomads, brokers and market makers. The link between negative newsflow and the share price performance remains intact. This is why I say take advantage of any spikes tomorrow but top up at your peril.
25/3/2018
13:01
miavoce: I've been invested in AGL for many years and I am fully familiar with the typical volume of trading and the share price behaviour. Maybe to aid your credibility on this thread you could perhaps comment on the likely forthcoming newsflow and its potential impact on the share price The combination of sensitivity and specificity which is achieved by the AGL test outperforms the two existing tests which either have much weaker sensitivity or much weaker specificity.
25/3/2018
12:37
pwhite73: miavoce - "I don't think PWhite realises that he / she is talking to a group of long term investors in Angle.." Over the years I have seen many a long term investors and supposed experts in British Biotech companies lose all their money. Firstly AGL is listed on the AIM which in itself is questionable. Secondly the company has been going for about 15 years. Its about the same age as PYC. It listed at a time when tiny British Biotechs were all the rage. At the last interims to 31/10/2017 revenue was just £200k for crying out and losses were £3.4m. In fact the Sunday Times article is old news and inaccurate. The company's report on 08/01/2018 showed the results were no different than the standard results just that the method of obtaining the results was different. They did not indicate an accuracy of 95.1% whilst results from other methods are lower. I have no doubt they are making some limited progress but you need to separate the company from the shenanigans of the AIM. Normally there are less than ten trades per day so the stock is not very liquid. You will be able to buy but not sell. If you are going to top up be careful. If the rise puts you into profit take advantage of it and reduce your holding. You will get another chance to top up at a cheaper price. turbocharge I have had this argument on many a thread. I am fully aware of the difference between the nominal value and the share price. When looking at future issues you look at the nominal value not the share price. Reason being the markets will try to sell you the stock at as close to the nominal value as possible that way the margin of profit is much large. If they are forward selling placing shares at 10p for 47p the profit margin is 37p. If they are forward selling placing shares at 40p for 47p the profit margin is only 7p.
06/3/2018
12:51
jelenko: I suspect there is an order to fill. As soon as it's filled it normally drops back a touch. Although, we are not too far from the MD Anderson lead Clinical Trial results(June/July), a few months which for longer term holders feels like days/weeks. I think we have good reason to expect positive results and Abbot piggybacking with HER2 evaluation it is likely to be a major turning point for AGL. The share price has not moved in step with the positive news flow over the last 12 months and it is fair to say that the company is still under the radar of most investors. I am personally expecting a gradual movement upwards as we get closer to June/July. It's quite difficult to predict what the share price may be in the future. I would be disappointed though if we do not challenge £1 on trial results rns. and £2.50 by the time of FDA approval.
24/12/2017
11:06
alloa2003: Its that time of year - what are your predicitons for the AGL share price in 12 months? I will start at £2 a share :)
13/9/2017
09:00
sicilian_kan: No miavoce I'm not suggesting that. That would be crazy to think. But companies have a degree of control over the release of news. E.g. when to sign the contract etc. They also have much greater control over when to time a placing and can time it around newsflow. So the two can go hand in hand and often do. Newland's problem is that he has left it far, far too late. I expect he initially would have preferred to place after the ovarian results, expecting the share price to rise, and then it didn't. Instead, the share price more than halved from its high. It kept on falling and was volatile. I doubt very much that this would have happened if Angle was well funded, which it is not. The market has driven the price down expecting funding needs and given the vagaries of the ovarian RNS with its claims of "up to 95%", which without more information as to what "up to" means is fairly useless. In summary, any fundraising in the 30p region will be a total failure. It will be raising funds at a near 5 year low, despite all the scientific progress. If you want any indictment on Newland, if he does place in the 30p region, that will be all the evidence you need to show his failings as a CEO. What Newland does is to head down incorrect paths (FDA approval), announcing unrealistic timetables (e.g. the repeated delays to ovarian), whilst looking after number one (i.e. himself) over and above the best interests of the company shareholders (his share sales and buybacks, accepting his far too high bonuses etc). For me, Newland has lost credibility. I just cannot rely upon his statements about timings etc. There are only so many times the pudding can (looking retrospectively) be overegged, however inadvertently. Of course, I accept that Angle has made massive progress scientifically and the company is a lot further ahead, but the share price is categorically in a bad, bad place. Many shareholders will be in a position of a loss and the potential dilution here will be significant. Yes, a deal or some other funding arrangement might come along that will be much better than a placing at these levels and could obviate the need for significant dilution. But given where the share price is, the market does not believe that this will be the case. The market may be wrong of course, but usually it is correct at times such as this one.
11/6/2017
15:55
alloa2003: Personally I think if AGL had taken this slowly slowly approach a couple of years ago the share price would be much higher. We have suffered from mismanagement of expectations but hopefully the BOD have learnt a lesson. Let the results come through and let them speak for themselves. Trying to guess when the FDA might act on AGL's application(s) is a waste of time but good trial results will put more pressure on the FDA. Share price targets of £5 are unrealistic at this moment in time but we could have a game changing year and a rejuvenated share price. First of all we need to see constant positive news flow and better management of expectations. The recent research note suggesting a share price of 187p (from memory) seems ambitious but achievable in this very volatile area in which AGL operates. One of the other keys is to maximise the current benefits of Parsortix over competing system asap - that way we get a foothold in the market. Once we are there, the companies who operate in this area will not be changing their systems every 2 minutes and only then will we see the sales flow that everyone has been hoping for.
Angle share price data is direct from the London Stock Exchange
Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P:42 V: D:20180427 08:33:48